OTC Pharmaceuticals North America (NAFTA) Industry Guide_2016

Date: October 20, 2016
Pages: 84
Price:
US$ 795.00
License [?]:
Publisher: MarketLine
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: OD6F99078FFEN
Leaflet:

Download PDF Leaflet

OTC Pharmaceuticals North America (NAFTA) Industry Guide_2016
SUMMARY

The NAFTA OTC Pharmaceuticals industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value and volume 2011-15, and forecast to 2020). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

KEY FINDINGS
  • Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the NAFTA otc pharmaceuticals market
  • Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the NAFTA otc pharmaceuticals market
  • Leading company profiles reveal details of key otc pharmaceuticals market players' NAFTA operations and financial performance
  • Add weight to presentations and pitches by understanding the future growth prospects of the NAFTA otc pharmaceuticals market with five year forecasts by both value and volume
  • Compares data from the US, Canada and Mexico, alongside individual chapters on each country
SYNOPSIS

Essential resource for top-line data and analysis covering the NAFTA otc pharmaceuticals market. Includes market size and segmentation data, textual and graphical analysis of market growth trends and leading companies.

REASONS TO BUY
  • What was the size of the NAFTA otc pharmaceuticals market by value in 2015?
  • What will be the size of the NAFTA otc pharmaceuticals market in 2020?
  • What factors are affecting the strength of competition in the NAFTA otc pharmaceuticals market?
  • How has the market performed over the last five years?
  • Who are the top competitors in the NAFTA otc pharmaceuticals market?
KEY HIGHLIGHTS
  • The North American Free Trade Agreement (NAFTA) is a trade agreement between the countries in North America: the US, Canada and Mexico. The otc pharmaceuticals industry within the NAFTA countries had a total market value of $43,365.6 million in 2015.The Mexico was the fastest growing country, with a CAGR of 4.2% over the 2011-15 period.
  • Within the otc pharmaceuticals industry, the US is the leading country among the NAFTA bloc, with market revenues of $38,718.7 million in 2015. This was followed by Canada and Mexico, with a value of $2,717.1 and $1,929.8 million, respectively.
  • The US is expected to lead the otc pharmaceuticals industry in the NAFTA bloc, with a value of $43,383.7 million in 2020, followed by Canada and Mexico with expected values of $3,139.6 and $2,385.5 million, respectively.
Introduction
What is this report about?
Who is the target reader?
How to use this report
Definitions
NAFTA OTC Pharmaceuticals
Industry Outlook
OTC Pharmaceuticals in Canada
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
OTC Pharmaceuticals in Mexico
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
OTC Pharmaceuticals in The United States
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Company Profiles
Leading companies
Appendix
Methodology
About MarketLine

LIST OF TABLES

Table 1: NAFTA countries otc pharmaceuticals industry, revenue ($m), 2011-20
Table 2: NAFTA countries otc pharmaceuticals industry, revenue ($m), 2011-15
Table 3: NAFTA countries otc pharmaceuticals industry forecast, revenue ($m), 2015-20
Table 4: Canada OTC pharmaceuticals market value: $ million, 2011-15
Table 5: Canada OTC pharmaceuticals market category segmentation: $ million, 2015
Table 6: Canada OTC pharmaceuticals market geography segmentation: $ million, 2015
Table 7: Canada OTC pharmaceuticals market share: % share, by value, 2015
Table 8: Canada OTC pharmaceuticals market distribution: % share, by value, 2015
Table 9: Canada OTC pharmaceuticals market value forecast: $ million, 2015-20
Table 10: Canada size of population (million), 2011-15
Table 11: Canada gdp (constant 2005 prices, $ billion), 2011-15
Table 12: Canada gdp (current prices, $ billion), 2011-15
Table 13: Canada inflation, 2011-15
Table 14: Canada consumer price index (absolute), 2011-15
Table 15: Canada exchange rate, 2011-15
Table 16: Mexico OTC pharmaceuticals market value: $ million, 2011-15
Table 17: Mexico OTC pharmaceuticals market category segmentation: $ million, 2015
Table 18: Mexico OTC pharmaceuticals market geography segmentation: $ million, 2015
Table 19: Mexico OTC pharmaceuticals market share: % share, by value, 2015
Table 20: Mexico OTC pharmaceuticals market distribution: % share, by value, 2015
Table 21: Mexico OTC pharmaceuticals market value forecast: $ million, 2015-20
Table 22: Mexico size of population (million), 2011-15
Table 23: Mexico gdp (constant 2005 prices, $ billion), 2011-15
Table 24: Mexico gdp (current prices, $ billion), 2011-15
Table 25: Mexico inflation, 2011-15
Table 26: Mexico consumer price index (absolute), 2011-15
Table 27: Mexico exchange rate, 2011-15
Table 28: United States OTC pharmaceuticals market value: $ million, 2011-15
Table 29: United States OTC pharmaceuticals market category segmentation: $ million, 2015
Table 30: United States OTC pharmaceuticals market geography segmentation: $ million, 2015
Table 31: United States OTC pharmaceuticals market share: % share, by value, 2015
Table 32: United States OTC pharmaceuticals market distribution: % share, by value, 2015
Table 33: United States OTC pharmaceuticals market value forecast: $ million, 2015-20
Table 34: United States size of population (million), 2011-15
Table 35: United States gdp (constant 2005 prices, $ billion), 2011-15
Table 36: United States gdp (current prices, $ billion), 2011-15
Table 37: United States inflation, 2011-15
Table 38: United States consumer price index (absolute), 2011-15
Table 39: United States exchange rate, 2011-15
Table 40: GlaxoSmithKline Plc: key facts
Table 41: GlaxoSmithKline Plc: key financials ($)
Table 42: GlaxoSmithKline Plc: key financials (£)
Table 43: GlaxoSmithKline Plc: key financial ratios
Table 44: Johnson and Johnson: key facts
Table 45: Johnson and Johnson: key financials ($)
Table 46: Johnson and Johnson: key financial ratios
Table 47: Pfizer Inc.: key facts
Table 48: Pfizer Inc.: key financials ($)
Table 49: Pfizer Inc.: key financial ratios
Table 50: Sanofi SA: key facts
Table 51: Sanofi SA: key financials ($)
Table 52: Sanofi SA: key financials (€)
Table 53: Sanofi SA: key financial ratios
Table 54: Bayer AG: key facts
Table 55: Bayer AG: key financials ($)
Table 56: Bayer AG: key financials (€)
Table 57: Bayer AG: key financial ratios
Table 58: Bristol Myers Squibb Company: key facts
Table 59: Bristol Myers Squibb Company: key financials ($)
Table 60: Bristol Myers Squibb Company: key financial ratios
Table 61: Royal DSM N.V.: key facts
Table 62: Royal DSM N.V.: key financials ($)
Table 63: Royal DSM N.V.: key financials (€)
Table 64: Royal DSM N.V.: key financial ratios

LIST OF FIGURES

Figure 1: NAFTA countries otc pharmaceuticals industry, revenue ($m), 2011-20
Figure 2: NAFTA countries otc pharmaceuticals industry, revenue ($m), 2011-15
Figure 3: NAFTA countries otc pharmaceuticals industry forecast, revenue ($m), 2015-20
Figure 4: Canada OTC pharmaceuticals market value: $ million, 2011-15
Figure 5: Canada OTC pharmaceuticals market category segmentation: % share, by value, 2015
Figure 6: Canada OTC pharmaceuticals market geography segmentation: % share, by value, 2015
Figure 7: Canada OTC pharmaceuticals market share: % share, by value, 2015
Figure 8: Canada OTC pharmaceuticals market distribution: % share, by value, 2015
Figure 9: Canada OTC pharmaceuticals market value forecast: $ million, 2015-20
Figure 10: Forces driving competition in the OTC pharmaceuticals market in Canada, 2015
Figure 11: Drivers of buyer power in the OTC pharmaceuticals market in Canada, 2015
Figure 12: Drivers of supplier power in the OTC pharmaceuticals market in Canada, 2015
Figure 13: Factors influencing the likelihood of new entrants in the OTC pharmaceuticals market in Canada, 2015
Figure 14: Factors influencing the threat of substitutes in the OTC pharmaceuticals market in Canada, 2015
Figure 15: Drivers of degree of rivalry in the OTC pharmaceuticals market in Canada, 2015
Figure 16: Mexico OTC pharmaceuticals market value: $ million, 2011-15
Figure 17: Mexico OTC pharmaceuticals market category segmentation: % share, by value, 2015
Figure 18: Mexico OTC pharmaceuticals market geography segmentation: % share, by value, 2015
Figure 19: Mexico OTC pharmaceuticals market share: % share, by value, 2015
Figure 20: Mexico OTC pharmaceuticals market distribution: % share, by value, 2015
Figure 21: Mexico OTC pharmaceuticals market value forecast: $ million, 2015-20
Figure 22: Forces driving competition in the OTC pharmaceuticals market in Mexico, 2015
Figure 23: Drivers of buyer power in the OTC pharmaceuticals market in Mexico, 2015
Figure 24: Drivers of supplier power in the OTC pharmaceuticals market in Mexico, 2015
Figure 25: Factors influencing the likelihood of new entrants in the OTC pharmaceuticals market in Mexico, 2015
Figure 26: Factors influencing the threat of substitutes in the OTC pharmaceuticals market in Mexico, 2015
Figure 27: Drivers of degree of rivalry in the OTC pharmaceuticals market in Mexico, 2015
Figure 28: United States OTC pharmaceuticals market value: $ million, 2011-15
Figure 29: United States OTC pharmaceuticals market category segmentation: % share, by value, 2015
Figure 30: United States OTC pharmaceuticals market geography segmentation: % share, by value, 2015
Figure 31: United States OTC pharmaceuticals market share: % share, by value, 2015
Figure 32: United States OTC pharmaceuticals market distribution: % share, by value, 2015
Figure 33: United States OTC pharmaceuticals market value forecast: $ million, 2015-20
Figure 34: Forces driving competition in the OTC pharmaceuticals market in the United States, 2015
Figure 35: Drivers of buyer power in the OTC pharmaceuticals market in the United States, 2015
Figure 36: Drivers of supplier power in the OTC pharmaceuticals market in the United States, 2015
Figure 37: Factors influencing the likelihood of new entrants in the OTC pharmaceuticals market in the United States, 2015
Figure 38: Factors influencing the threat of substitutes in the OTC pharmaceuticals market in the United States, 2015
Figure 39: Drivers of degree of rivalry in the OTC pharmaceuticals market in the United States, 2015
Figure 40: GlaxoSmithKline Plc: revenues and profitability
Figure 41: GlaxoSmithKline Plc: assets and liabilities
Figure 42: Johnson and Johnson: revenues and profitability
Figure 43: Johnson and Johnson: assets and liabilities
Figure 44: Pfizer Inc.: revenues and profitability
Figure 45: Pfizer Inc.: assets and liabilities
Figure 46: Sanofi SA: revenues and profitability
Figure 47: Sanofi SA: assets and liabilities
Figure 48: Bayer AG: revenues and profitability
Figure 49: Bayer AG: assets and liabilities
Figure 50: Bristol Myers Squibb Company: revenues and profitability
Figure 51: Bristol Myers Squibb Company: assets and liabilities
Figure 52: Royal DSM N.V.: revenues and profitability
Figure 53: Royal DSM N.V.: assets and liabilities
Skip to top


Tobacco North America (NAFTA) Industry Guide 2016 US$ 795.00 Jul, 2016 · 85 pages

Ask Your Question

OTC Pharmaceuticals North America (NAFTA) Industry Guide_2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: